# A Study to Determine the Efficacy, Safety, and Durability of Faricimab in Participants With Neovascular Age-Related Macular Degeneration

> **NCT06795048** · PHASE4 · ACTIVE_NOT_RECRUITING · sponsor: **Hoffmann-La Roche** · enrollment: 274 (estimated)

## Conditions studied

- Neovascular Age-related Macular Degeneration (nAMD)

## Interventions

- **DRUG:** Faricimab

## Key facts

- **NCT ID:** NCT06795048
- **Lead sponsor:** Hoffmann-La Roche
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2025-03-14
- **Primary completion:** 2026-10-15
- **Final completion:** 2027-09-16
- **Target enrollment:** 274 (ESTIMATED)
- **Last updated:** 2026-04-30


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06795048

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06795048, "A Study to Determine the Efficacy, Safety, and Durability of Faricimab in Participants With Neovascular Age-Related Macular Degeneration". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT06795048. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*